Dennis M McNamara1, Anne L Taylor2, S William Tam3, Manuel Worcel4, Clyde W Yancy5, Karen Hanley-Yanez6, Jay N Cohn7, Arthur M Feldman8. 1. Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: mcnamaradm@upmc.edu. 2. Columbia University College of Physicians and Surgeons, New York, New York. 3. Independent consultant, Dover, Massachusetts. 4. Consultant, Paris, France. 5. Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 6. Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 7. University of Minnesota, Minneapolis, Minnesota. 8. Temple University School of Medicine, Philadelphia, Pennsylvania.
Abstract
OBJECTIVES: The purpose of this study was to evaluate the influence of the guanine nucleotide-binding proteins (G-proteins), beta-3 subunit (GNB3) genotype on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in A-HeFT (African American Heart Failure Trial). BACKGROUND: GNB3 plays a role in alpha2-adrenergic signaling. A polymorphism (C825T) exists, and the T allele is linked to enhanced alpha-adrenergic tone and is more prevalent in African Americans. METHODS: A total of 350 subjects enrolled in the genetic substudy (GRAHF [Genetic Risk Assessment of Heart Failure in African Americans]) were genotyped for the C825T polymorphism. The impact of FDC I/H on a composite score (CS) that incorporated death, hospital stay for heart failure, and change in quality of life (QoL) and on event-free survival were assessed in GNB3 genotype subsets. RESULTS:The GRAHF cohort was 60% male, 25% ischemic, 97% New York Heart Association functional class III, age 57 ± 13 years, with a mean qualifying left ventricular ejection fraction of 0.24 ± 0.06. For GNB3 genotype, 184 subjects were TT (53%), 137 (39%) CT, and 29 (8%) were CC. In GNB3 TT subjects, FDC I/H improved the CS (FDC I/H = 0.50 ± 1.6; placebo = -0.11 ± 1.8, p = 0.02), QoL (FDC I/H = 0.69 ± 1.4; placebo = 0.24 ± 1.5, p = 0.04), and event-free survival (hazard ratio: 0.51, p = 0.047), but not in subjects with the C allele (for CS, FDC I/H = -0.05 ± 1.7; placebo = -0.09 ± 1.7, p = 0.87; for QoL, FDC I/H = 0.28 ± 1.5; placebo = 0.14 ± 1.5, p = 0.56; and for event-free survival, p = 0.35). CONCLUSIONS: The GNB3 TT genotype was associated with greater therapeutic effect of FDC I/H in A-HeFT. The role of the GNB3 genotype for targeting therapy with FDC I/H deserves further study.
RCT Entities:
OBJECTIVES: The purpose of this study was to evaluate the influence of the guanine nucleotide-binding proteins (G-proteins), beta-3 subunit (GNB3) genotype on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in A-HeFT (African American Heart Failure Trial). BACKGROUND:GNB3 plays a role in alpha2-adrenergic signaling. A polymorphism (C825T) exists, and the T allele is linked to enhanced alpha-adrenergic tone and is more prevalent in African Americans. METHODS: A total of 350 subjects enrolled in the genetic substudy (GRAHF [Genetic Risk Assessment of Heart Failure in African Americans]) were genotyped for the C825T polymorphism. The impact of FDC I/H on a composite score (CS) that incorporated death, hospital stay for heart failure, and change in quality of life (QoL) and on event-free survival were assessed in GNB3 genotype subsets. RESULTS: The GRAHF cohort was 60% male, 25% ischemic, 97% New York Heart Association functional class III, age 57 ± 13 years, with a mean qualifying left ventricular ejection fraction of 0.24 ± 0.06. For GNB3 genotype, 184 subjects were TT (53%), 137 (39%) CT, and 29 (8%) were CC. In GNB3 TT subjects, FDC I/H improved the CS (FDC I/H = 0.50 ± 1.6; placebo = -0.11 ± 1.8, p = 0.02), QoL (FDC I/H = 0.69 ± 1.4; placebo = 0.24 ± 1.5, p = 0.04), and event-free survival (hazard ratio: 0.51, p = 0.047), but not in subjects with the C allele (for CS, FDC I/H = -0.05 ± 1.7; placebo = -0.09 ± 1.7, p = 0.87; for QoL, FDC I/H = 0.28 ± 1.5; placebo = 0.14 ± 1.5, p = 0.56; and for event-free survival, p = 0.35). CONCLUSIONS: The GNB3 TT genotype was associated with greater therapeutic effect of FDC I/H in A-HeFT. The role of the GNB3 genotype for targeting therapy with FDC I/H deserves further study.
Authors: Arthur M Feldman; Christopher D Kontos; Joseph M McClung; Glenn S Gerhard; Kamel Khalili; Joseph Y Cheung Journal: Circ Heart Fail Date: 2017-06 Impact factor: 8.790
Authors: Richard Sheppard; Eileen Hsich; Julie Damp; Uri Elkayam; Angela Kealey; Gautam Ramani; Mark Zucker; Jeffrey D Alexis; Benjamin D Horne; Karen Hanley-Yanez; Jessica Pisarcik; Indrani Halder; James D Fett; Dennis M McNamara Journal: Circ Heart Fail Date: 2016-03 Impact factor: 8.790
Authors: Amber E Johnson; Karen Hanley-Yanez; Clyde W Yancy; Anne L Taylor; Arthur M Feldman; Dennis M McNamara Journal: J Card Fail Date: 2019-04-09 Impact factor: 5.712
Authors: Prateeti Khazanie; Li Liang; Lesley H Curtis; Javed Butler; Zubin J Eapen; Paul A Heidenreich; Deepak L Bhatt; Eric D Peterson; Clyde W Yancy; Gregg C Fonarow; Adrian F Hernandez Journal: Circ Heart Fail Date: 2016-02 Impact factor: 8.790
Authors: Mathew R Taylor; Albert Y Sun; Gordon Davis; Mona Fiuzat; Stephen B Liggett; Michael R Bristow Journal: JACC Heart Fail Date: 2014-10-22 Impact factor: 12.035
Authors: Jimmy T Efird; Andy C Kiser; Patricia B Crane; Hope Landrine; Linda C Kindell; Margaret-Ann Nelson; Charulata Jindal; Daniel F Sarpong; William F Griffin; T Bruce Ferguson; W Randolph Chitwood; Stephen W Davies; Alan P Kypson; Preeti Gudimella; Ethan J Anderson Journal: Pharmacotherapy Date: 2017-02-03 Impact factor: 4.705
Authors: Amber Johnson; Stephen Broughton; Lisa Aponte-Soto; Karriem Watson; Carla Da Goia Pinto; Philip Empey; Steven Reis; Robert Winn; Mylynda Massart Journal: Ethn Dis Date: 2020-04-02 Impact factor: 1.847
Authors: Tarek Magdy; Adam J T Schuldt; Joseph C Wu; Daniel Bernstein; Paul W Burridge Journal: Annu Rev Pharmacol Toxicol Date: 2017-10-06 Impact factor: 13.820